Buda Juice Inc

Buda Juice Inc (BUDA) Stock Analysis

$6.550

-0.069 (-1.06%)At close

Loading chart…
High
7.115
Open
7.115
VWAP
6.65
Volume
5.98K
Mkt Cap
—
Low
6.300
Amount
39.81K
EV/EBITDA, TTM
27.16

Buda Juice, Inc. operates in a beverage industry, focused on UltraFresh juice-offering cold-crafted citrus-based drinks. The Company offers an end-to-end cold chain platform that always delivers cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. Its product portfolio consists of fresh citrus juice, a fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using its cold chain process. Its products include Buda Juice (Organic), Buda Fresh - Value-Forward Offering (Non-Organic), and Private Label Products (Non-organic and Organic). Buda Fresh includes Fresh 12 oz Lime Juice, 16 oz and 128 oz Lemon Juice, Fresh Orange and Grapefruit Juice (16 oz, 32 oz and 52 oz), and Fresh Citrus-based Lemonades and Limeades (16 oz and 52 oz). Private Label Products include Fresh Citrus Line (52 oz) and Fresh Citrus-based Lemonades and Limeades (52 oz).

AI analysis of Buda Juice Inc (BUDA)

Buy

Buda Juice appears to be a strong buy at the current price of $7.22, especially with an RSI of 62.22 indicating bullish momentum. The stock has a significant upside potential with an analyst price target of $12, suggesting a potential gain of 66.67%. Additionally, the company has shown robust revenue growth, with Q2 2026 revenue reaching $4.5 million, a substantial increase compared to previous quarters. However, investors should be cautious of the forward P/E ratio of 49.02, which indicates that the stock may be overvalued if growth does not meet expectations.

Valuation Metrics

The current forward P/E ratio for Buda Juice Inc (BUDA) is 49.26, compared to its 5-year average forward P/E of 48.93.

Forward P/E

Fair
5Y Average P/E
48.93
Current P/E
49.26
Overvalued
50.18
Undervalued
47.68

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
49.93
Current EV/EBITDA
27.16
Overvalued
179.76
Undervalued
-79.90

Forward P/S

Fair
5Y Average P/S
170.84
Current P/S
4.00
Overvalued
1138.27
Undervalued
-796.59

Events Timeline

2026-08-13 (ET)

07:30:00

Buda Juice Reports Q2 Revenue of $4.5M

2026-05-26 (ET)

07:10:00

Buda Juice Dual Lists on NYSE Texas Effective May 26, 2026

2026-05-13 (ET)

07:10:00

Buda Juice Reports Q1 Adjusted EPS of 5 Cents, Revenue of $3.5M

2026-05-11 (ET)

07:00:00

Buda Juice Launches New Drink in 246 Walmart Stores

2026-03-26 (ET)

07:10:00

Buda Juice Reports FY25 Revenue of $12.6M

News

BUDA FAQ — answered by Alphio AI

Buda Juice, Inc. operates in a beverage industry, focused on UltraFresh juice-offering cold-crafted citrus-based drinks. The Company offers an end-to-end cold chain platform that always delivers cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. Its product portfolio consists of fresh citrus juice, a fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using its cold chain process. Its products include Buda Juice (Organic), Buda Fresh - Value-Forward Offering (Non-Organic), and Private Label Products (Non-organic and Organic). Buda Fresh includes Fresh 12 oz Lime Juice, 16 oz and 128 oz Lemon Juice, Fresh Orange and Grapefruit Juice (16 oz, 32 oz and 52 oz), and Fresh Citrus-based Lemonades and Limeades (16 oz and 52 oz). Private Label Products include Fresh Citrus Line (52 oz) and Fresh Citrus-based Lemonades and Limeades (52 oz). It operates in the Consumer Non-Cyclicals sector.

Buda Juice appears to be a strong buy at the current price of $7.22, especially with an RSI of 62.22 indicating bullish momentum. The stock has a significant upside potential with an analyst price target of $12, suggesting a potential gain of 66.67%. Additionally, the company has shown robust revenue growth, with Q2 2026 revenue reaching $4.5 million, a substantial increase compared to previous quarters. However, investors should be cautious of the forward P/E ratio of 49.02, which indicates that the stock may be overvalued if growth does not meet expectations.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading